Black Diamond Therapeutics
BDTX1.7301.70% ( -0.030 )
Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetical...
- Open
- 1.770
- High
- 1.845
- Low
- 1.725
- Prev. Close
- 1.760
- Volume
- 625.21K
- Turnover
- 1.11M
- Avg Price
- 1.774
- Bid/Ask Ratio
- --
- Amplitude
- 6.82%
- 52wk High
- 4.940
- Volume Ratio
- 1.10
- Turnover Ratio
- 1.19%
Black Diamond Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 2, 2026Price forecast
$9.86469.78%
Forecast & RatingStrong buy
9analysts
- Strong buy66.67%
- Buy22.22%
- Hold11.11%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 17 at 11:40 PM
Black Diamond Therapeutics (NASDAQ:BDTX) Trading Down 1.1% - Here's What Happened
- Global Report · Jul 9 at 05:02 AM
Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 Breakouts
- PUBT · Jun 29 at 03:21 PM
Black Diamond Therapeutics holds annual stockholder meeting via webcast
- Market Beat · Jun 6 at 04:04 AM
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
- benzinga_article · May 26 at 10:31 AM
What's Going On With Black Diamond Therapeutics Stock Tuesday?
- benzinga_article · May 22 at 12:05 PM
12 Health Care Stocks Moving In Friday's Intraday Session
